Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Digital Health Briefs: 2013 Funding; Telehealth Visits; Mental Health Apps

This article was originally published in The Gray Sheet

  • News

Executive Summary

Rock Health releases 2013 digital health trend report. Small pilot study of telehealth visits for Parkinson’s patients. Mental health apps scrutinized. More digital health briefs.

You may also be interested in...



Digital Health Briefs: Shuren On Interoperability; Apple CDRH Meeting; Topol At AT&T

CDRH Director Jeffrey Shuren offers FDA updates on interoperability. Apple meets with CDRH. More digital health in brief.

Digital Health Briefs: Apple Hires Medical Sensor Experts; Glooko Partnership

Apple hires medical sensor talent. Glooko partners with Joplin Diabetes Center. NIH director praises ZioPatch study. More digital health news.

Digital Health In Brief

Federal Communications Commission finalizes medical body area network rule. More digital health news.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

See All
UsernamePublicRestriction

Register

MT032789

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By